Current options for cannabinoids in the treatment of Parkinson's disease
DOI:
https://doi.org/10.12775/QS.2024.17.52922Keywords
cannabidiol, cannabinoids, CBD, Parkinson disease, PD, THCAbstract
The utility of cannabinoids as agents used to treat diseases is a popular topic of discussion these days. The approval of medical marijuana continues to stir up controversy. As far back as ancient times, hemp was used for medicinal purposes. These plants have the ability to produce phytochemicals and other compounds such as flavonoids and terpenes. Respective species of hemp differ in the content of particular chemical compounds and therefore have different possible uses. Among the best-known phytocannabinoids found in hemp are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). They have partially opposing effects and interact with the corresponding receptors of the endocannabinoid system in the body's tissues. We also distinguish between cannabinoids of endogenous origin - endocannabinoids (EC) and synthetic cannabinoids (SC). The effects of THC and CBD on the human body are still being studied. Information about them that appears in the media, is often reported inaccurately or incompletely. There is now a growing body of research into the use of cannabinoids to treat and alleviate the symptoms of many diseases. Due to the neuroprotective effects of THC and CBD, researchers' work has focused on using them to treat neurodegenerative diseases, which include Parkinson's disease (PD).
References
Costa AC, Joaquim HPG, Pedrazzi JFC, Pain AO, Duque G, Aprahamian I. Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges. Brain Sci. 2022 Nov 22;12(12):1596. doi: 10.3390/brainsci12121596.
Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Parkinson’s Foundation P4 Group. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018 Jul 10;4:21. doi: 10.1038/s41531-018-0058-0
Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002.
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May;20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447.
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Par-kinson disease (2009). Neurology. 2009 May 26;72(21 Suppl 4):S1-136. doi: 10.1212/WNL.0b013e3181a1d44c.
Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 1985 Nov;18(5):537-43. doi: 10.1002/ana.410180505.
Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021 Feb 25;7(1):16. doi: 10.1038/s41572-021-00247-4.
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Canna-bidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. doi: 10.1159/000521683.
Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol. 2022 Oct 25;13:989717. doi: 10.3389/fphar.2022.989717.
Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a The-rapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkin-son's Disease. Front Pharmacol. 2020 Dec 15;11:595635. doi: 10.3389/fphar.2020.595635.
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci. 2021 Aug 31;22(17):9472. doi: 10.3390/ijms22179472.
Cooray R, Gupta V, Suphioglu C. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review. Mol Neurobiol. 2020 Nov;57(11):4878-4890. doi: 10.1007/s12035-020-02054-6.
Buhmann C, Mainka T, Ebersbach G, Gandor F. Evidence for the use of cannabinoids in Parkinson's disease. J Neural Transm (Vienna). 2019 Jul;126(7):913-924. doi: 10.1007/s00702-019-02018-8.
Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psy-chiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016/j.biopsych.2015.07.028.
Stella N. THC and CBD: Similarities and differences between siblings. Neuron. 2023 Feb 1;111(3):302-327. doi: 10.1016/j.neuron.2022.12.022.
.Santos NA, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RH, et al. The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):231-40. doi: 10.1016/j.tiv.2015.11.004.
Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, et al. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Par-kinson's disease. Neurobiol Dis. 2020 Jul;141:104892. doi: 10.1016/j.nbd.2020.104892..
Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020.
Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4. doi: 10.1097/WNF.0000000000000016.
Shohet A, Khlebtovsky A, Roizen N, Roditi Y, Djaldetti R. Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease. Eur J Pain. 2017 Mar;21(3):486-493. doi: 10.1002/ejp.942. Epub 2016 Oct 10.
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179.
Dos-Santos-Pereira M, da-Silva CA, Guimarães FS, Del-Bel E. Co-administration of can-nabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action. Neurobiol Dis. 2016 Oct;94:179-95. doi: 10.1016/j.nbd.2016.06.013.
de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol. 2020 Feb;34(2):189-196. doi: 10.1177/0269881119895536.
Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci. 1986 Nov;30(4):277-82. doi: 10.3109/00207458608985678. PMID: 3793381.
Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. Cannabi-diol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009 Nov;23(8):979-83. doi: 10.1177/0269881108096519.
Peball M, Krismer F, Knaus HG, Djamshidian A, Werkmann M, Carbone F, et al. Colla-borators of the Parkinson's Disease Working Group Innsbruck. Non-Motor Symptoms in Par-kinson's Disease are Reduced by Nabilone. Ann Neurol. 2020 Oct;88(4):712-722. doi: 10.1002/ana.25864.
Gruber MT, Witte OW, Grosskreutz J, Prell T. Association between malnutrition, clinical parameters and health-related quality of life in elderly hospitalized patients with Parkinson's disease: A cross-sectional study. PLoS One. 2020 May 4;15(5):e0232764. doi: 10.1371/journal.pone.0232764.
Lee CM, Neighbors C, Woods BA. Marijuana motives: young adults' reasons for using marijuana. Addict Behav. 2007 Jul;32(7):1384-94. doi: 10.1016/j.addbeh.2006.09.010.
Moitra E, Christopher PP, Anderson BJ, Stein MD. Coping-motivated marijuana use cor-relates with DSM-5 cannabis use disorder and psychological distress among emerging adults. Psychol Addict Behav. 2015 Sep;29(3):627-32. doi: 10.1037/adb0000083.
Bonn-Miller MO, Vujanovic AA, Zvolensky MJ. Emotional dysregulation: association with coping-oriented marijuana use motives among current marijuana users. Subst Use Mi-suse. 2008;43(11):1653-65. doi: 10.1080/10826080802241292.
Buckner JD, Bonn-Miller MO, Zvolensky MJ, Schmidt NB. Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav. 2007 Oct;32(10):2238-52. doi: 10.1016/j.addbeh.2007.04.004.
Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc. 2013 Oct;19(9):1009-15. doi: 10.1017/S135561771300088X.
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1-13. doi: 10.3109/15563650.2015.1110590.
Müller HH, Kornhuber J, Sperling W. The behavioral profile of spice and synthetic can-nabinoids in humans. Brain Res Bull. 2016 Sep;126(Pt 1):3-7. doi: 10.1016/j.brainresbull.2015.10.013.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psy-chiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8.
Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020 Sep;22(3):241-250. doi: 10.31887/DCNS.2020.22.3/rspanagel.
Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Associa-tion Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016 Sep;42(5):1262-9. doi: 10.1093/schbul/sbw003.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Piotr Zdzieblo, Ewelina Machała-Ćwikła, Urszula Łapińska, Piotr Ćwikła, Kamila Machała, Anna Zdziebło, Dominika Machała, Katarzyna Zdzieblo, Anna Bieniasz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 99
Number of citations: 0
